Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

about

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Item

http://www.wikidata.org/entity/Q52686509

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Bortezomib plus dexamethasone ...... r refractory multiple myeloma.

@en

Bortezomib plus dexamethasone ...... r refractory multiple myeloma.

@nl

type

Item

label

Bortezomib plus dexamethasone ...... r refractory multiple myeloma.

@en

Bortezomib plus dexamethasone ...... r refractory multiple myeloma.

@nl

prefLabel

Bortezomib plus dexamethasone ...... r refractory multiple myeloma.

@en

Bortezomib plus dexamethasone ...... r refractory multiple myeloma.

@nl

P1476

Bortezomib plus dexamethasone ...... or refractory multiple myeloma

@en

P2093

Hiroaki Asai

http://www.w3.org/2001/XMLSchema#string

Hirokazu Nagai

http://www.w3.org/2001/XMLSchema#string

Ichiro Hanamura

http://www.w3.org/2001/XMLSchema#string

Junya Kuroda

http://www.w3.org/2001/XMLSchema#string

Kazuhito Yamamoto

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Shimada

http://www.w3.org/2001/XMLSchema#string

Kenichi Miyamoto

http://www.w3.org/2001/XMLSchema#string

Kensei Tobinai

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Ando

http://www.w3.org/2001/XMLSchema#string

Kunihiro Tsukasaki

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

P304

1552-1561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13550

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Dai Maruyama

Shinsuke Iida

P577

2018-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29478257

http://www.w3.org/2001/XMLSchema#string

P921

thalidomide

dexamethasone

P932

5980148

http://www.w3.org/2001/XMLSchema#string